PML-RARα and Dnmt3a1 Cooperate in vivo to Promote Acute Promyelocytic Leukemia

D Subramanyam, CD Belair, KQ Barry-Holson, H Lin… - Cancer research, 2010 - AACR
D Subramanyam, CD Belair, KQ Barry-Holson, H Lin, SC Kogan, E Passegué, R Blelloch
Cancer research, 2010AACR
The PML-RARα oncogene is the central effector of acute promyelocytic leukemia (APL).
PML-RARα physically interacts with epigenetic-modifying enzymes including DNA
methyltransferases (Dnmt) to suppress critical downstream targets. Here, we show that
increased expression of Dnmt3a1 cooperates with PML-RARα in vivo to promote early
lethality secondary to myeloid expansion and dysfunction in primary mice. Bone marrow
cells from these mice cause leukemogenesis with a shortened latency and a higher …
Abstract
The PML-RARα oncogene is the central effector of acute promyelocytic leukemia (APL). PML-RARα physically interacts with epigenetic-modifying enzymes including DNA methyltransferases (Dnmt) to suppress critical downstream targets. Here, we show that increased expression of Dnmt3a1 cooperates with PML-RARα in vivo to promote early lethality secondary to myeloid expansion and dysfunction in primary mice. Bone marrow cells from these mice cause leukemogenesis with a shortened latency and a higher penetrance on transplantation into irradiated recipients. Furthermore, leukemic cells overexpressing PML-RARα and Dnmt3a1 display increased methylation at a target promoter compared with PML-RARα or Dnmt3a1 controls. Our findings show a cooperation between the PML-RARα oncogene and the Dnmt3a1 enzyme in vivo and that Dnmt levels can be rate limiting in APL progression. Cancer Res; 70(21); 8792–801. ©2010 AACR.
AACR